Business Description
Citius Oncology Inc
NAICS : 325412
SIC : 2834
ISIN : US17331Y1091
Description
Citius Oncology Inc is a biopharmaceutical company focused on developing and commercializing targeted oncology therapies.The Company centers on achieving a market position by advancing therapies with reduced development and clinical risks, and competitive advantages supported by intellectual property and regulatory exclusivity protection. This includes new formulations of previously approved drugs with substantial existing safety and efficacy data or expanded indications for approved therapies. The company focused on key geographies and stakeholders, majorly on cancer centers and patients.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.69 | |||||
Equity-to-Asset | 0.35 | |||||
Debt-to-Equity | 0.11 | |||||
Debt-to-EBITDA | -0.1 | |||||
Piotroski F-Score | N/A/9 | |||||
Altman Z-Score | -2.4 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -67.8 | |||||
3-Year EPS without NRI Growth Rate | -64.8 | |||||
3-Year Book Growth Rate | 1.8 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 51.32 | |||||
9-Day RSI | 46.97 | |||||
14-Day RSI | 44.52 | |||||
3-1 Month Momentum % | 11.31 | |||||
6-1 Month Momentum % | -27.55 | |||||
12-1 Month Momentum % | -85.01 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.5 | |||||
Quick Ratio | 0.12 | |||||
Cash Ratio | 0.04 | |||||
Days Inventory | 6538.27 | |||||
Days Sales Outstanding | 166.79 | |||||
Days Payable | 3193.46 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -5.4 | |||||
Shareholder Yield % | -23.31 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 80.08 | |||||
Operating Margin % | -775.67 | |||||
Net Margin % | -757.64 | |||||
EBITDA Margin % | -701.46 | |||||
FCF Margin % | -288.49 | |||||
OCF Margin % | -199.38 | |||||
ROE % | -102.89 | |||||
ROA % | -42.96 | |||||
ROIC % | -59.73 | |||||
3-Year ROIIC % | -55.89 | |||||
ROCE % | -87.13 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 6.19 | |||||
PS Ratio | 10.98 | |||||
PB Ratio | 1.79 | |||||
EV-to-EBIT | -1.55 | |||||
EV-to-EBITDA | -1.64 | |||||
EV-to-Revenue | 11.48 | |||||
EV-to-Forward-Revenue | 3.16 | |||||
EV-to-FCF | -3.98 | |||||
Earnings Yield (Greenblatt) % | -64.52 | |||||
FCF Yield % | -25.59 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:CTOR
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Citius Oncology Inc Executives
DetailsGF Value™
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 5.611 | ||
| EPS (TTM) ($) | -0.47 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 84.24 | ||
| 14-Day RSI | 44.52 | ||
| 14-Day ATR ($) | 0.065184 | ||
| 20-Day SMA ($) | 0.69424 | ||
| 12-1 Month Momentum % | -85.01 | ||
| 52-Week Range ($) | 0.4912 - 5.8899 | ||
| Shares Outstanding (Mil) | 92.98 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9999 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Citius Oncology Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Citius Oncology Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Annual report for 2026 | 2026-12-23 | In 173 days | ||
| Fourth quarter earnings results for 2026 | 2026-12-23 | In 173 days | ||
| General meeting for 2025 | 2026-10-27 08:00 | In 117 days | ||
| Third quarter earnings results for 2026 | 2026-08-12 | In 40 days | ||
| Second quarter earnings results for 2026 | 2026-05-15 | 0.98 (+1.47%) | ||
| First quarter earnings results for 2026 | 2026-02-13 | 1.18 (+6.31%) | ||
| Annual report for 2025 | 2025-12-23 | 1.25 (-10.07%) | ||
| Fourth quarter earnings results for 2025 | 2025-12-23 | 1.25 (-10.07%) | ||
| General meeting for 2024 | 2025-10-27 08:00 | 1.72 (+1.78%) | ||
| Third quarter earnings results for 2025 | 2025-08-12 | 1.72 (-3.37%) |
Show
Entries
Citius Oncology Inc Frequently Asked Questions
What is Citius Oncology Inc(CTOR)'s stock price today?
The current price of CTOR is $0.68. The 52 week high of CTOR is $5.89 and 52 week low is $0.49.
When is next earnings date of Citius Oncology Inc(CTOR)?
The next earnings date of Citius Oncology Inc(CTOR) is 2026-08-12 Est..
Does Citius Oncology Inc(CTOR) pay dividends? If so, how much?
Citius Oncology Inc(CTOR) does not pay dividend.
Guru Commentaries on NAS:CTOR
No articles.
Press Release
Articles on Citius Oncology Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers